Edition:
United Kingdom

People: Lantheus Holdings Inc (LNTH.OQ)

LNTH.OQ on NASDAQ Stock Exchange Global Market

27.67USD
22 Jul 2019
Change (% chg)

$-0.59 (-2.09%)
Prev Close
$28.26
Open
$28.50
Day's High
$28.50
Day's Low
$27.59
Volume
84,992
Avg. Vol
119,017
52-wk High
$29.80
52-wk Low
$12.60

Markison, Brian 

Mr. Brian A. Markison is the Non-Executive Independent Chairman of Lantheus Holdings Inc. He is the Non-Executive Chairman of the Board and Chair of the Financing and Strategy Committee. Mr. Markison joined the Board in September 2012 and was elevated to Chairman in January 2013. Mr. Markison has been a Healthcare Industry Executive for Avista Capital Partners since September 2012. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He is currently the Chief Executive Officer and a Director of Osmotica Holdings, S.C.Sp., after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King, Mr. Markison held various senior leadership positions at Bristol-Meyers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison also serves on the Board of Directors of National Spine Centers LLC, on the Board of Directors of Braeburn Pharmaceuticals, and on the Board of Directors of Cosette Pharmaceuticals. He is also a Director of the College of New Jersey. Mr. Markison holds a Bachelor of Science degree from Iona College.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 116,854
Fiscal Year Total, USD 116,854

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Brian Markison

116,854

Mary Heino

3,913,930

Robert Marshall

974,734

John Bolla

--

Michael Duffy

1,198,260

Sarah Roy

--
As Of  31 Dec 2018